Study Summary
This trial is testing a new drug, RO7444973, for safety and effectiveness in people with unresectable and/or metastatic melanoma-associated antigen A4 (MAGE-A4)-positive, solid tumors who carry the HLA-A*02:01 allele.
- Solid Tumors
Treatment Effectiveness
Effectiveness Progress
Study Objectives
2 Primary · 7 Secondary · Reporting Duration: From baseline to death from any cause (up to 40 months)
Trial Safety
Safety Progress
Trial Design
3 Treatment Groups
Part I: Single Participant Cohort (SPC) Dose Escalation
1 of 3
Part II: Multiple Participant Cohort (MPC) Dose Escalation
1 of 3
Part III: Recommended Phase 2 Dose (RP2D) Expansion
1 of 3
Experimental Treatment
260 Total Participants · 3 Treatment Groups
Primary Treatment: RO7444973 · No Placebo Group · Phase 1
Trial Logistics
Trial Timeline
Who is running the clinical trial?
Eligibility Criteria
Age 18+ · All Participants · 12 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Frequently Asked Questions
Has the FDA sanctioned RO7444973 for clinical application?
"The safety of RO7444973 is estimated to be a 1, since this study is in its first phase and there exists little data regarding both efficacy and security." - Anonymous Online Contributor
Are there numerous sites administering this research within the city?
"This research program is being conducted by the University of Florida in Gainesville, Yale Cancer Center's Medical Oncology department located in Detroit and Henry Ford Hospital situated in Hackensack. Additionally, there are 7 other participating sites involved." - Anonymous Online Contributor
What other exploratory tests have been done with RO7444973?
"At present, RO7444973 is being tested in 71 clinical trials; with 8 of those studies firmly situated within Phase 3. Though the majority are found in Poznan and New York City, there are 1455 other locations around the world conducting research on this medication." - Anonymous Online Contributor
Are there any enrollments being accepted for this research endeavor at present?
"Affirmative. According to the clinicaltrials.gov website, this trial began recruitment on January 25th 2022 and is currently ongoing. A total of 260 patients are sought after across 7 medical sites." - Anonymous Online Contributor
What have physicians been recommending RO7444973 for lately?
"RO7444973 is a medication primarily used to treat polyarticular juvenile idiopathic arthritis. Additionally, it can help patients with sjia, cytokine release syndrome caused by car-t cell therapy, and giant cells manage their medical conditions." - Anonymous Online Contributor
What is the maximum capacity for participants in this research?
"For the trial to be considered successful, a total of 260 participants that meet the necessary prerequisites must be recruited. Hoffmann-La Roche will manage this study from two separate sites - University of Florida in Gainesville and Yale Cancer Center's Medical Oncology branch in Detroit." - Anonymous Online Contributor